Lantheus Holdings Inc (LNTH)

Over the past six months, Lantheus reported strong Q1 2026 financial results, exceeding EPS and revenue forecasts, which led to a stock price increase. The company received FDA approval for PYLARIFY TruVu and tentative approval for PNT2003. The PDUFA date for LNTH-2501 was extended to June 29, 2026. The stock has shown a significant return over the past six months and year-to-date, with analysts adjusting price targets higher.

While recent performance indicates a slowdown in overall annualized revenue growth, there is no specific information available detailing seasonal demand fluctuations for Lantheus Holdings, Inc.'s products and services. DEFINITY, a cardiology product, experienced a year-over-year increase in revenue, suggesting that demand for individual products may vary.

Lantheus Holdings, Inc. is a radiopharmaceutical company focused on improving patient outcomes through diagnostic and therapeutic products. The company's offerings are categorized into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Key products include PYLARIFY (piflufolastat F 18) injection, DEFINITY, TechneLite, and NEURACEQ. Pipeline products include LNTH-2501 (Ga 68 edotreotide) and MK-6240.

Lantheus is headquartered in Massachusetts, USA, with additional offices in New Jersey, Canada, Germany, Sweden, Switzerland, and the United Kingdom. The company markets and sells its products in the United States, primarily to hospitals, independent imaging centers, and government facilities. Outside the U.S., Lantheus distributes its products through direct and third-party relationships and licensing arrangements across Europe, Canada, Australia, Asia-Pacific, Central America, and South America.

Lantheus Holdings, Inc.'s brand reputation over the past year appears to be favorable, driven by positive financial results and regulatory milestones such as FDA approvals for PYLARIFY TruVu and tentative approval for PNT2003. There is no readily available information suggesting any major negative events that have significantly impacted Lantheus's reputation in the past year.

Lantheus Holdings, Inc. has a significant level of institutional ownership, including major shareholders such as BlackRock, Inc., Vanguard Group Inc, and Janus Henderson Group Plc. Sriram Venkataraman is the largest individual shareholder, owning 21.24 million shares, representing 32.87% of the company.